Familial hypercholesterolaemia (FH) is the most common and serious form of inherited dyslipidaemia, and is characterised by elevated total cholesterol and low density lipoprotein-cholesterol (LDL-C) levels in the plasma from birth. Increased lifelong exposure to LDL-C accelerates the atherogenic process, placing patients at cumulatively higher risk of premature cardiovascular disease.

Timely diagnosis and treatment initiation are crucial to ensuring favourable patient outcomes. This requires active discovery of FH index cases, and opportunistic cascade screening of their families. With early, aggressive intervention, including pharmacological therapy and lifestyle modifications, patients can generally be assured of a normal or improved life expectancy.

This eLearning module discusses the identification and management of FH in clinical practice, and presents a family case study.